Merus (NASDAQ:MRUS) Earns Outperform Rating from William Blair

William Blair restated their outperform rating on shares of Merus (NASDAQ:MRUS) in a report issued on Monday morning, RTT News reports.

Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets boosted their price target on shares of Merus from $49.00 to $58.00 and gave the stock an outperform rating in a research report on Thursday, February 29th. Truist Financial began coverage on shares of Merus in a research note on Thursday, March 28th. They set a buy rating and a $69.00 price objective on the stock. HC Wainwright boosted their price objective on shares of Merus from $48.00 to $65.00 and gave the stock a buy rating in a research note on Thursday, February 29th. Stifel Nicolaus boosted their price objective on shares of Merus from $40.00 to $65.00 and gave the stock a buy rating in a research note on Thursday, February 29th. Finally, StockNews.com lowered shares of Merus from a hold rating to a sell rating in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $56.33.

Merus Price Performance

Shares of NASDAQ:MRUS opened at $41.97 on Monday. The company’s 50-day moving average price is $45.03 and its two-hundred day moving average price is $33.52. Merus has a one year low of $18.21 and a one year high of $52.03. The stock has a market capitalization of $2.46 billion, a PE ratio of -13.81 and a beta of 1.10.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.38). Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. The business had revenue of $8.94 million for the quarter, compared to the consensus estimate of $10.43 million. On average, analysts anticipate that Merus will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MRUS. AE Wealth Management LLC grew its stake in Merus by 14.2% in the 3rd quarter. AE Wealth Management LLC now owns 22,500 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 2,801 shares during the last quarter. Mach 1 Financial Group LLC grew its position in shares of Merus by 13.9% during the 3rd quarter. Mach 1 Financial Group LLC now owns 22,435 shares of the biotechnology company’s stock worth $529,000 after purchasing an additional 2,736 shares in the last quarter. BluePath Capital Management LLC acquired a new position in shares of Merus during the 3rd quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. grew its position in shares of Merus by 142.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 867 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of Merus by 47.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 12,084 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 3,916 shares in the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.